Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43853   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Study title: Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging : Frühwald MC, Rickert CH, O'Dorisio MS, Madsen M, Warmuth-Metz M, Khanna G, Paulus W, Kühl J, Jürgens H, Schneider P, Müller HL; Clin Cancer Res. 2004 May 1;10(9):2997-3006
    Active substance: (111In) INDIUM CHLORIDE/PENTETREOTIDE
    Study summary document link (including results):
    View full study record
    Document reference: 21232
    Study title: Patients with seasonal allergic rhinitis, conjunctivitis and possobly asthma symptoms so far only statistical analysis, Publication sheduled. Age of patients: 5 - 79 Years
    Active substance: 158 Rye
    Study summary document link (including results):
    View full study record
    Document reference: 39753
    Study title: Abacavir pharmacokinetics during chronic therapy in HIV-1 infected adolescents and young adults
    Active substance: abacavir
    Study summary document link (including results):
    View full study record
    Document reference: 41628
    Study title: Prospective, multicenter, observational study to document therapeutic data relating to treatment with Abropernol (tablets) [AWB-AT]
    Active substance: Abropernol - Tabletten
    Study summary document link (including results):
    View full study record
    Document reference: 39760
    Study title: Retrospective survey for documentation of appllication and dosage of Abropernol N (tablets) in children < 12 years of age [Bef-014]
    Active substance: Abropernol - Tabletten
    Study summary document link (including results):
    View full study record
    Document reference: 39761
    Study title: Prospective, multicenter, observational study to document therapeutic data relating to treatment with Abropernol (tablets) [AWB-AT]
    Active substance: Abropernol N
    Study summary document link (including results):
    View full study record
    Document reference: 39762
    Study title:
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_Rating D_Gryzewski N_1982_publication.pdf
    View full study record
    Document reference: 46891
    Study title: ACARBOSE (BAY G 5421) IN INSULIN-DEPENDENT DIABETES - THE EFFECT ON THE DAILY BLOOD-GLUCOSE PROFILE AND ON THE INSULINCONSUMPTION BY AN ARTIFICIAL PANCREAS (STUDY 0160)(PH-9873)
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0160_study_synopsis.pdf
    View full study record
    Document reference: 46154
    Study title: ACARBOSE AS AN ADJUNCT IN THE MANAGEMENT OF JUVENILE ONSET DIABETESACARBOSE AS AN ADJUNCT IN THE MANAGEMENT OF JUVENILE ONSET DIABETES
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_Bartsocas CS_1982_publication.pdf
    View full study record
    Document reference: 46889
    Study title: Assessment of efficacy and tolerability of Acarbose in children under 16 years
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_9981_study_synopsis.pdf
    View full study record
    Document reference: 46160
    Study title: Clinical Study on the Efficacy and Tolerability of Acarbose (BAY g 5421) Compared with Placeboin Diabetic Children on Conventional Insulin Treatment, in Particular with Observation of the Glycemic Control Index ( PH-24820 )
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0665_study_synopsis.pdf
    View full study record
    Document reference: 46158
    Study title: Clinical Study to Investigate the Efficacy and Tolerability of Acarbose (BAY g 5421) Versus Placebo in Diabetic Children (PH 23433)
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0634_study_synopsis.pdf
    View full study record
    Document reference: 46155
    Study title: Double-Blind, Cross-Over Clinical Study at a Single Centre to Compare Acarbose (BAY g 5421) with Placebo in Respect of Efficacy and Tolerability in Patients with Cystic Fibrosis and Pathological Glucose Tolerance (Pilot Study)(PH-26068)
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0696_study_synopsis.pdf
    View full study record
    Document reference: 46159
    Study title: Guillet J, Blanquet P, Guillet G, Mollard S, Massicot P, Maleville J. The use of technetium Tc 99m medronate scintigraphy as a prognostic guide in childhood dermatomyositis. Arch Dermatol. 1981 Aug;117(8):451. No abstract available. Guillet J, Blanquet P, Guillet G, Mollard S, Massicot P, Maleville J. The use of technetium Tc 99m medronate scintigraphy as a prognostic guide in childhood dermatomyositis. Arch Dermatol. 1981 Aug;117(8):451. No abstract available.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 44115
    Study title: NON RANDOMISED FOLLW-UP STUDY WITH ACARBOSE-TREATMENT AND PRE- AND AFTER-TREATMENT WITH PLACEBO IN DIABETIC CHILDREN (TYPE I) STUDY 0428 (PH 14352)
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0428_study_synopsis.pdf
    View full study record
    Document reference: 46156
    Study title: The effect of acarbose (Bay G 5421) on the insulin consumption of children treated with insulin.
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0221_study_synopsis.pdf
    View full study record
    Document reference: 46157
    Study title: The modification of sucrose absorption by acarboseThe modification of sucrose absorption by acarbose
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_Rating D_1982_publication.pdf
    View full study record
    Document reference: 46890
    Study title: Blockers and hypoglycaemia (assesment of cadioselective and intrinsic sympathometic properties in relation to severity of hypoglycaemia - No author - 1984 (Current Therapeutic Research 36, n° 2, p. 361-373) ; - Publication in Documentation clinique du dossier d'AMM du 30/10/1987 -
    Active substance: ACEBUTOLOL
    Study summary document link (including results):
    View full study record
    Document reference: 46182
    Study title: Clinical and echocardiographic (echo) long-term follow-up of children with severe hypertension (HT) - Loirat C. et al. - No date (Hopital Bretonneau, INSERM U 120, Paris) ; - Publication in Documentation clinique du dossier d'AMM du 30/10/1987 -
    Active substance: ACEBUTOLOL
    Study summary document link (including results):
    View full study record
    Document reference: 46183
    Study title: Clinical pharmacology and therapeutic utilization of anti-hypertensive agents in children - Mirkin B.L., Sinaiko - 1977 In : (New M.I., Levine L.S. Juvenile hypertension, pp. 195-218. New-York, Raven Press.) - Publication in expertise clinique pour le dossier français de demande d'extension des indications thérapeutiques de Sectral 200mg comprimés, au traitement de l'hypertension artérielle de l'enfant - Pr Broyer - 14/06/1983 -
    Active substance: ACEBUTOLOL
    Study summary document link (including results):
    View full study record
    Document reference: 46184
    1  2  3  4  5  6  7  8  9  Next» Last»»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Apr 23 08:53:35 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA